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Summary 
Polymerase chain reaction amplification of cDNA for acidic fibroblast  growth factor in several 
lines of cultured human cells revealed two forms of mRNA. The novel smaller mRNA lacks 
the entire second coding exon of the acidic fibroblast growth factor gene, whereas the previously 
identified mRNA consists of three coding exons. The truncated variant of acidic fibroblast growth 
factor (aFGF') is only 60 amino acids long with an apparent molecular mass of 6.7 kD on sodium 
dodecyl sulfate gels in contrast to 18 kD for the full-length acidic fibroblast growth factor, aFGF' 
elicits only minimal fibroblast proliferation and antagonizes the effects of acidic fibroblast growth 
factor when added exogenously to or when coexpressed with aFGF in BALB/c/3T3 fibroblasts. 
Thus, the truncated variant of acidic fibroblast  growth factor may provide fibroblasts  with a 
unique mechanism for endogenous regulation of their responses to acidic fibroblast growth factor. 
T 
he fibroblast growth factor (FGF) 1 family presently con- 
sists of seven different proteins that have mitogenic and 
chemotactic activities  for a wide variety of mesoderm- and 
neuroectoderm-derived  cells (1). Acidic FGF (aFGF) and basic 
FGF (bFGF) are expressed in normal tissues as well as tumors, 
where they contribute to wound healing and angiogenesis, 
and may have important roles in cellular development and 
physiology (1-5). Although the mechanisms of release of aFGF 
and bFGF from cells have not been defined, they act specifically 
by binding to high-affinity cellular receptors.  FGF receptors 
belong to the tyrosine kinase family of receptors (6), which 
are activated by FGF binding and result in the phosphoryla- 
tion of tyrosine residues in the receptor cytoplasmic domain 
and other cellular substrates (7). Another consequence of the 
activation of FGF receptors is a dramatic increase of expres- 
sion of the protooncogene c-fis (8). Two members of the FGF 
family, int-2 (9) and hst/Ks3 (10), are products of putative 
oncogenes, and aFGF and bFGF also have transforming poten- 
tial as demonstrated by the effects of transfection of the respec- 
tive genes into fibroblasts (11). The genes for FGFs are highly 
conserved among species and are similar in their overall or- 
ganization of three coding exons separated by two large in- 
trons.  In the case of aFGF, two additional upstream non- 
I Abbreviations used in this paper: aFGE acidic fibroblast growth factor; 
bFGF,  basic fibroblast  growth factor;  RP,  reversed-phase; RT,  reverse 
transcription. 
coding exons have been identified recently that are alternatively 
spliced to the first coding exon (12). In addition, multiple 
polyadenylation sites lead to a highly heterogeneous aFGF 
mRNA pattern (13). 
In the course of our studies, which aimed at the analysis 
of the expression  of aFGF in several human cell lines with 
the help of the reverse transcription polymerase chain reac- 
tion (RT-PCK) methodology, we discovered that next to the 
expected cDNA made up of all three coding exons, an addi- 
tional smaller cDNA is amplified that is missing the entire 
second coding exon of the aFGF gene. The alternate aFGF 
mRNA encodes a 60-amino acid protein that we termed 
aFGF'. We describe here our studies with synthetic aFGF', 
which indicate that the newly found alternate form acts like 
an antagonist for aFGF. 
Materials  and Methods 
Cell Culture.  Human lung fibroblasts  (obtained  from a lung 
biopsy), human dermal fibroblasts  CR.L 1564, human medullo- 
blastoma  TE671 ceils,  and murine BALB/c/3T3 fibroblasts  (UCSF 
Tissue  Culture Facility)  were  cultured  as  monolayers in  DME  1-121 
supplemented with 10% heat-inactivated  FCS, 4.5  g/liter  glucose, 
25 mM  Hepes, 10  s U/liter  penicillin-G,  and I0  s U/liter  strep- 
tomycin sulfate.  Human umbilical  vein  endothelial  cells  (Clonetics, 
San Diego, CA) were cultured  in  growth medium EGM-UV  (CIo- 
netics).  Ceils  were grown at 37~  in 5% CO2 in air  and split  at 
1:4 after they had reached confluency. 
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isolated  from 10  s human lung fibroblasts  and reverse transcribed 
with an oligo(dT) primer (Pharmacia LKB, Piscataway, NJ). PCR 
amplification of the resultant single-stranded cDNA mixture was 
carried out with primers 5'CGGGAAT~TCTTGAAAGCGCCA- 
CAAGCAGCAG 3' and 5'ACGAGAATTCTCTGGAGTGGTCA- 
ACACCCA 3', which include EcoRI adaptor sites at their ends 
and recognize the flanking sequence ends of a 531-bp cDNA en- 
coding the entire human aFGF. The PCR reaction mix consisted 
of 58.5 #1 of sterile double-distilled water, 10/~1 of 10x  reaction 
buffer,  16/~1 of 1.25 mM dNTP mix, 0.5 #1 of Taq polymerase 
(Promega Corp., Madison, WI),  5 #1 of each of the primers at 
20/zM, and 5/xl of single-stranded cDNAs. Each of the 35 cycles 
performed in a PCR thermocycler (Perkin Elmer Cetus, Norwalk, 
CT) included denaturation at 94~  for 30 s, reannealing of primers 
and fragments at 55~  for 1 min, and primer extension at 72~ 
for 2 rain. The resultant cDNA products were analyzed on a 3% 
agarose  gel. 
Cloning and Sequencing.  DNA fragments amplified by PCR were 
purified on agarose gel and electroeluted, repaired with Klenow, 
kinased,  and cloned into a SmaI-  (or EcoRI)-digested and phos- 
phatase-treated  Mp13M18 vector. DNA sequencing was performed 
on single-stranded M13 DNA by the dideoxy chain termination 
method. 
Bacterial Expression ofaFGF',  aFGF' was expressed as a protein 
A  fusion protein using  the pRIT5 vector (Pharmacia  LKB) in 
Staphylococcal aureus according to the manufacturer's instructions. 
After isolation of the fusion protein with the help of an IgG- 
Sepharose column (Pharmacia LKB), the purified protein was sub- 
jected to cyanogen bromide cleavage (14), which results in an aFGF' 
form that is lacking the first methionine residue. Final purification 
of aFGF' (amino acids 2-60) was carried out by reversed-phase high 
performance liquid chromatography (RP-HPLC) and peptide iden- 
tity confirmed by gas-phase protein sequence analysis. 
Peptide Synthesis.  The aFGF' protein was chemically synthesized 
with a peptide synthesizer (431; Applied Biosystems,  Inc., Foster 
City, CA). Amino acids were coupled as their FMOC derivatives 
(Bachem, Torrance,  CA). Peptides  were deprotected and cleaved 
off the resin with TFA/anisol/dimethylsulfide/ethanedithiol (93: 
3:3:1) and purified by RP-HPLC. Peptide identity was confirmed 
by gas-phase  sequence and mass spectrometric analyses. 
Western Blot.  The polyclonal antiserum for the immunoblot was 
prepared by immunizing rabbits with synthetic aFGF', or was ob- 
tained from a commercial source (directed against epitopes derived 
from exons 2 and 3 of the aFGF gene; Promega Corp.). Proteins 
extracted from the nuclear fraction of 103 confluent human lung 
fibroblasts  with SDS-PAGE sample buffer were resolved on 14% 
SDS-polyacrylamide  gels and transferred onto nitrocellulose mem- 
branes.  The membranes  bearing blot-transferred proteins  were 
soaked in a blocking buffer of 5% nonfat dry milk in 150 mM 
NaC1, 50 mM Tris-HC1, pH 7.5, for 2 h at room temperature and 
then incubated with antiserum or preimmune serum at a 1:500 
dilution in blocking buffer. IgG bound to transferred proteins was 
detected with the alkaline phosphatase system, as described by the 
manufacturer (Promega Corp.). 
Mitogenesis Assays.  The mitogenic effects of aFGF and aFGF' 
(recombinant as well as chemically synthesized forms of the pro- 
tein were used and had identical activities)  alone and in combina- 
tion were determined by measuring their ability to stimulate up- 
take of [3H]thymidine by BALB/c/3T3 cells. 5  x  103 BALB/c/ 
3T3 cells were seeded into each well of 96-weU plates,  grown to 
confluence in cuhure medium, starved for 7 d, and then stimulated 
with either human recombinant aFGF (Promega Corp.) or recom- 
binant aFGF' for 24 h, followed by addition of I/~Ci of [3H]thy- 
midine (Amersham Corp., Arlington Heights, IL) to each well. 
After 10 h of further incubation, the cells were detached and dis- 
persed with trypsin, deposited onto individual glass fiber filters for 
determination with a cell harvester of incorporated [3H]thymidine 
in a scintillation counter. 
Affinity Crosslinking of ~2SI-aFGF  ' to Fibroblast Receptors.  BALB/ 
c/3T3 cells were grown to confluence in 60-mm wells, and washed 
twice with 10 ml of cold in PBS before addition of I ml of binding 
buffer (DME H21 with 25 mM Hepes, pH 7.5, 0.2% gelatin) and 
12SI-aFGF' (2  x  1@ cpm). Control wells designed to assess non- 
specific labeling also received a 100-fold excess of unlabeled aFGF'. 
2 ml of disuccinimidyl suberate,  which had been diluted from a 
concentration of 20 mM in DMSO to 0.15 mM in PBS at room 
temperature, was added to each well. After crosslinking at room 
temperature for 15 min, the incubation medium was aspirated, each 
well was washed twice with 10 ml of cold PBS, and the cells were 
removed with a pipette tip in 200/~1 of SDS-PAGE sample buffer. 
The cellular lysates were incubated at 4~  for 10 rain, boiled for 
5 rain, and a 50-/~1 portion was loaded onto a 7.5% SDS-poly- 
acrylamide gel and subjected to electrophoresis. The gels then were 
soaked in EN3HANCE (Amersham Corp.), dried, and autoradi- 
ographed. 
Binding Studies.  4  ￿  104 BALB/c/3T3 cells were seeded into 
16-ram-diameter  wells and grown to confluency. The adherent cells 
were washed once with 0.25 ml of cold PBS and incubated in 0.5 
ml of the binding buffer (see above) for 60 min at 4~  with various 
amounts of 12SI-aFGF, radiolabehd with iodobeads  (Pierce Chem- 
ical Co.,  Rockford, IL) and Na12SI (Amersham Corp.), with or 
without  10/~g of unlabeled aFGF'. 
Analysis ofc-fos Expression.  BALB/c/3T3 cells were grown to 
confluency and starved in serum-free medium for 48 h. The cells 
were then incubated with either aFGF (50 ng/ml),  aFGF' (18.6 
ng/ml), or medium alone for 10, 20, and 30 rain. RNA was ex- 
tracted from each  suspension  of cells by the  guanidinium  iso- 
thiocyanate (GIT)-CsC1 ultracentrifugation method, and 10/~g of 
RNA  was  each  fractionated  on  a  1%  agarose  gel  containing 
2.2 M formaldehyde in lx  3-(N-morpholino) propanesulfonic acid 
(MOPS) buffer, and transferred to a nitrocellulose filter in 10x 
SSC.  The filter was probed with 100 ng of a randomly primed 
3~p-labeled c-fos cDNA fragment (generated by PCR with c-J0s- 
specific primers) and washed once for 20 min at room temperature 
in lx  SSC, 0.1% SDS, and three times for 20 min each at 68~ 
in 0.2x SSC, 0.1% SDS, dried, and exposed to x-ray film at - 70~ 
Generation of Stable Transfectants.  The coding sequences for aFGF 
and aFGF' were cloned into the mammalian transfection vector 
pRC/CMV (Pharmacia LKB) and the recombinant plasmids trans- 
fected into BALB/c/3T3 cells by the lipofection (Bethesda Research 
Laboratories, Gaithersburg, MD) procedure. Briefly, 10/~g of the 
plasmid was mixed with the lipofectin reagent, and after 15 min 
incubation time at room temperature, the DNA lipofectin mix- 
ture was  mixed with 3T3 cells in a FCS-free optimen medium 
(Bethesda  Research Laboratories).  After 24 h, the optimen media 
was removed and replaced with DME and 10% FCS.  For selec- 
tion, 500/~g/ml geneticin antibiotic (Gibco Laboratories,  Grand 
Island,  NY) was added to the culture, and incubation continued 
for 2 wk, at which time geneticin-resistant colonies were visible. 
Individual colonies were then transferred to 17-mm wells and grown 
up.  All transfectants were assessed for their mRNA levels using 
a ribonuclease protection assay (see below). 
Ribonuclease Protection Assay.  An RNA probe complementary 
to the entire coding region of the aFGF gene was used and was 
generated by transcription from the pbCIIKS + plasmid (Strata- 
1074  Alternative  Acidic Fibroblast Growth Factor gene, La JoUa, CA) in the presence of [3ZP]dUTP. R.NA synthesis 
was carried out with T3 polymerase and the RNA purified on a 
5% preparative polyacrylamide gel. 10  s cpm of the labeled RNA 
probe was then coprecipitated with 50/~g total RNA, the RNA 
pellet dissolved in 30/~1 of 80% formamide,  400 mM NaCI,  40 
mM Pipes (pH 6.4),  and 1 mM EDTA (pH 8). After heating  at 
850C for 10 min, hybridization  was performed at 420C for 12 h. 
Subsequently, 297/~1 of lx  RNase buffer (5 ml 300 mM sodium 
acetate, pH 7, 0.5  ml 10 mM Tris-HC1, pH 7.5, 0.5  ml 5 mM 
EDTA, pH 8) was added along with 1/~1 of RNase A (10 mg/ml) 
and 2/~1 of RNase T1 (10 mg/ml).  After a 30-min incubation  at 
30~  6.6/~1 of 10% SDS and 4.4/~1 of proteinase K (10 mg/ml) 
were added and incubated for 15 min at 42~  The mixture was 
then extracted  with phenol/chloroforrn/isoamylalcohol,  and the 
protected RNA was precipitated by adding 1.5 #1 tRNA (10 mg/ml) 
and 800/xl ethanol.  The pellet was dissolved in 30/xl of 80% for- 
mamide,  1 x  TBE,  1 mM EDTA, 0.5% bromophenol blue,  and 
0.05% xylene cyanol, denatured  at 95~  for 5 min and resolved 
on a 5% polyacrylamide gel. Dried gels were exposed to x-ray film 
at  -70~  for 12 h. To assess the ratio of aFGF' and aFGF mRNA 
in the cotransfectant cell lines, gel pieces corresponding to the three 
protected RNA fragments were cut out, and radioactivity was mea- 
sured with a scintillation  counter. 
Proliferation  Assay.  On day O, 30,000 cells were seeded into 60- 
mm dishes in DME supplemented with 5% FCS. After 5 d, tripli- 
cate dishes were trypsinized, and the cell number was assessed  with 
a cell counter (Coulter  Electronics,  Inc.,  Hialeah,  FL). 
Results 
Analysis ofaFGF Expression.  PCR amplification of cDNA 
templates derived from mRNA of different human cultured 
ceils (lung fibroblasts,  dermal fibroblasts,  and medulloblastoma 
ceils), with oligonucleotide primers specific for the aFGF gene, 
yielded two cDNAs of distinct  sizes  (Fig.  1).  One cDNA 
was ",,500 bp, expected for aFGF, and the other cDNA was 
--100  bp  smaller.  Only  the  previously  identified  531-bp 
cDNA was cleaved by PstI into the predicted fragments of 
212 and 319 bp, whereas the smaller cDNA species appeared 
to lack the unique PstI cleavage site located within  exon 2 
of the aFGF  gene (data not  shown).  Complete  nucleotide 
sequence analysis confirmed the absence of the entire second 
Figure 1.  Expression  of aFGF 
in human lung fibroblasts. Aga- 
rose gel electrophoresis of RT- 
PCR amplification products (see 
Materials and  Methods). Two 
cDNA  species were amplified 
from human lung fibroblasts  with 
specific oligonucleotide primers 
flanking the coding region of the 
aFGF gene. Lane 1, lung fibro- 
blasts cDNA template; lane 2, 
negative control (no template); 
lane 3,  DNA  molecular mass 
markers. 
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exon of the aFGF gene from the smaller aFGF cDNA, which 
was designated aFGF' (Fig. 2). Further evidence that the above 
cells expressed an mRNA species lacking the second coding 
exon was obtained by a ribonuclease protection assay with 
an antisense aFGF RNA probe that encompassed the entire 
coding sequence of the aFGF gene. Next to the expected full- 
length aFGF mRNA (536 bp), the probe also protected two 
RNA species  that  represented  fragments corresponding  to 
the first (230 bp) and third (203 bp) coding exons of the aFGF 
gene and were derived from  the  aFGF' mRNA  (Fig.  3). 
The lack of the second exon in the smaller aFGF' mRNA, 
which is presumably the consequence of alternative splicing, 
shifts  the reading  frame to create a premature  termination 
of translation  12 nucleotides  downstream  from the begin- 
ning  of the  third  exon.  The  loss of 104  coding base pairs 
of exon 2 combined with an early termination of translation 
yields an alternate  aFGF' protein,  which is only 60 amino 
acids long,  of which,  56 are identical to the NH2-terminal 
end of aFGF  (Fig.  2). 
Analysis ofaFGF' Activities.  For functional and biochemical 
analyses, both recombinant and chemically synthesized aFGF' 
were prepared  (see Materials  and Methods).  Synthetic and 
recombinant  aFGF' had identical activities in all assays (see 
below) and also served as the immunogen to generate poly- 
clonal antibodies in rabbits. Western blots of nuclear extracts 
from quiescent human lung fibroblasts were probed with the 
polyclonal antiserum  raised against  aFGF' (Fig.  4). Besides 
several nonspecific high molecular mass proteins in both lanes, 
two proteins were detected by the immuneserum (Fig. 4, lane 
2), but not preimmune  serum (Fig.  4, lane 3), which were 
competed by excess aFGF' peptide (data not shown) and have 
sizes  of 18 and 7 kD.  These are presumed to be aFGF and 
aFGF', respectively, since they are comigrating with human 
recombinant aFGF and aFGF' on SDS gels (Fig.  4, lane 1). 
Western  blots  carried  out  with  commercial  antisera  (see 
Materials and Methods) directed against aFGF epitopes en- 
coded by exons 2 and 3 showed only the 18-kD protein signal, 
which argues against  the possibility that  the 7-kD protein 
is a degradation product of aFGF (data not shown). The newly 
discovered variant of aFGF mRNA hence codes for a protein 
of the size expected for a deletion of the second exon and 
a premature stop codon. Although it appears that the signal 
for aFGF is more intense than  that for aFGF', it is difficult 
to assess the exact ratio of the two proteins using this type 
of analysis.  Attempts  to detect immunoreactive proteins in 
total  cellular  extracts  failed,  presumably  due  to  the  small 
amounts of material.  Only enrichment  of the nuclear frac- 
tion yielded sufficient aFGF and aFGF' that could be detected 
with  the  above method. 
Since aFGF is a very potent mitogen for a wide range of 
mesodermal and neuroectodermal cells (1), mitogenesis assays 
were performed to examine the biological activity of the al- 
ternate aFGF', aFGF' has only a minimal mitogenic potential 
for fibroblasts as compared with the commercial full-length 
aFGF (half-maximal activity in the absence of heparin is 20 
ng/ml),  when  assessed  by  increases  in  the  uptake  of 
[3H]thymidine  into  murine  BALB/c/3T3  (Fig.  5  A)  and 
human  umbilical  vein  endothelial  cells  (data  not  shown). 1  21  41 
CTGCTGAGCCATGGCTGAAGGGGAAATCACCACCTTCACAGCCCTGACCGAGAAGTTTAA 
MetAlaGluGlyGluIleThrThrPheThrA1aLeuThrG1uLysPheAs 
61  81  I01 
TCTGCCTCCAGGGAATTACAAGAAGCCCAAACTCCTCTACTGTAGCAACGGGGGCCACTT 
nLeuProProGlyAsnTyrLysLysProLysLeuLeuTyrCysSerAsnGlyGlyHisPh 
121  141  161 
CCTGAGGATCCTTCCGGATGGCACAGTGGATGGGACAAGGGACAGGAGCGACCAGCACAT 
eLeuArgIleLeuProAspGlyThrValAspGlyThrArgAmpArgSerAmpGlnHisIl 
181  201  221 
TCAGCTGCAGCTCAGTGCGGAAAGCGTGGGGGAGGTGTATATAAAGAGTACCGAGACTGG 
eG1nLeuG1nLeuSerAlaGluSerVaiGlyGluValTyrIleLysSerThrGluThrGl 
241  261  28~ 
CCAGTACTTGGCCATGGACACCGACGGG~qq~ATACGGCTCACAGAC~CC&AATGAGGA 
yGlnTyrLeuAlaMetAspThrAspGlyLeuLeuTyrGlySerGlnThrProAsnGluGl 
301  321  341 
ATGTTTGTTCCTGGAAAGGCTGGAGGAGAACCATTACAACACCTATATATCCAAGAAGCA 
uCysLeuPheLeuGluArgLeuGluG1uAsnHisTyrAsnThrTyrIleSerLysLysHi 
361  381  401 
TGCAGAGAAGAATTGGTTTGTTGGCCTCAAGAAGAATGGGAGCTGCAAACGCGGTCCTCG 
sA1aGluLysAsnTrpPheValGlyLeuLysLysAsnGlySerCysLysArgGlyProAr 
421  441  461 
GACTCACTATGGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAGTCTCTTCTGATTAAAG 
gThrHisTyrG1yGlnLysAlaIleLeuPheLeuProLeuProValSerSerAsp*** 
481 
AGATCTGTTC 
AFGF 
1  21  41 
CTGCTGAGCCATGGCTGAAGGGGAAATCACCACCTTCACAGCCCTGACCGAGAAGTTTAA 
MetA1aGluGlyGluIleThrThrPheThrAlaLeuThrG1uLysPheAs 
61  81  101 
TCTGCCTCCAGGGAATTACAAGAAGCCCAAACTCCTCTACTGTAGCAACGGGGGCCACTT 
nLeuProProGlyAsnTyrLysLysProLysLeuLeuTyrCysSerAsnGlyGlyHisPh 
121  141  161 
CCTGAGGATCCTTCCGGATGGCACAGTGGATGGGACAAGGGACAGGAGCGACCAGCACAC 
eLeuArgIleLeuProAspGlyThrValAspGlyThrArqAmpArgSerAspGlnHisTh 
181  201  221 
AGACACCAAATGAGGAATGTTTGTTCCTGGAAAGGCTGGAGGAGAACCATTACAACACCT 
rAspThrLys*** 
241  261  281 
ATATATCCAAGAAGCATGCAGAGAAGAATTGGTTTGTTGGCCTCAAGAAGAATGGGAGCT 
301  321  341 
GCAAACGCGGTCCTCGGACTCACTATGGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAG 
261  381 
TCTCTTCTGATTAAAGAGATCTGTTC 
AFGF' 
Figure 2.  Structures  ofaFGF and aFGF. DNA 
fragments  obtained by RT-PCR were cloned into 
an Mp13M18 vector as described in Materials and 
Methods,  and DNA sequence was obtained by the 
dideoxy  chain  termination method.  The aFGF' 
cDNA lacks the entire second exon (boundaries 
marked  by arrows  in aFGF cDNA sequence) of 
the aFGF gene and codes for a protein of 60 amino 
acids. 
Figure 3.  Pdbonuclease protec- 
tion assay of human lung fibro- 
blast RNA. An aFGF riboprobe 
complementary to the coding re- 
gion of the aFGF  gene was  in- 
cubated  with  lung  fibroblast 
RNA and processed as described 
in Materials and Methods.  Lanes 
1 and 2 represent the results of two 
experiments  using  human  lung 
fibroblast  RNA; lane 3 contains 
RNA molecular  mass standards. 
The arrows indicate the positions 
of the protected RNA fragments, 
which are 536 bp for aFGF, and 
230 and  203 bp for aFGF'. 
When 50 ng/ml concentrations of aFGF were assayed in the 
presence of increasing amounts of recombinant or synthetic 
aFGF',  the mitogenic  potential  of aFGF was competitively 
inhibited by aFGF' (Fig. 5 B). In a control experiment, similar 
excess of an irrelevant  protein of similar size (insulin) did not 
inhibit  the  activity  of aFGF  (data  not  shown). 
The mitogenic potential of aFGF is significantly increased 
in the presence  of heparin,  to which all FGFs bind with a 
rather  high affinity (15).  Recently,  it  had been found that 
the principal site on the aFGF protein that binds to heparin 
is  made up of an amino  acid  sequence  encoded by exon 3 
(8).  As  predicted  by  the  truncated  structure  of aFGF',  no 
heparin  binding  was  detected  when  synthetic  aFGF'  was 
incubated with heparin sepharose (data not shown). Conse- 
quently, the minimal effect of aFGF' on fibroblast mitogenesis 
was not potentiated by heparin, which enhanced substantially 
1076  Alternative  Acidic  Fibroblast Growth Factor Figure 4.  Immunoblot  of SDS- 
PAGE of nuclear  extracts  of 10  s 
human lung fibroblasts developed 
with anti-aFGF' antiserum.  Lane 
2, immune serum; lane 3 preim- 
mune serum. Arrows indicate the 
positions  of recombinant  aFGF 
and aFGF' protein bands that were 
run in lane 1 and probed with im- 
mune serum. Positions of molec- 
ular  mass standards  are marked. 
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Figure 5.  (A) Effects of increasing  amounts of aFGF alone, aFGF  + 
10x  molar excess of aFGF', and aFGF' alone on fibroblast  mitogenesis 
as assessed by the uptake of [3H]thymidine into fibroblast DNA (n  =  5). 
The half-maximal activity of commercial aFGF was 20 ng/ml. (O) aFGF; 
(O) aFGF +  10x  molar excess aFGF'; (A) aFGF'. (B) Effects of increasing 
amounts of aFGF' on fibroblast mitogenesis  induced by 50 ng/ml aFGF. 
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Figure 6.  aFGF' binding to the FGF receptor. (A) Af~nity crosslinking 
of 12SI-aFGF' to flbroblast  receptors. Confluent BALB/c/3T3  cells were 
crosslinked with either  *2SI-aFGF'  alone (lane 2) or with a 100-fold excess 
of unlabeled  aFGF' (lane 1).  The arrow indicates  the position of cross- 
linked receptor  protein.  (B) Binding  assay. Confluent BALB/c/3T3 cells 
were incubated with radiolabeled aFGF with or without an excess amount 
of aFGF' (n  =  3).  (O)  12SI-aFGF; (A)  12SI-aFGF +  10/~g unlabeled 
aFGF'. 
the activity of aFGF and had no effects on the antagonistic 
activities of aFGF'  (data not  shown). 
Affinity crosslinking of 12SI-aFGF' to the aFGF receptor 
and analysis of the radiolabeled cellular protein by SDS-PAGE 
and autoradiography showed a broad band with an apparent 
molecular mass of 145 kD (Fig. 6 A, lane 2), which was not 
found in the presence of an excess amount of unlabeled aFGF' 
(Fig. 6 A, lane I). The size of the labeled protein is in good 
agreement  with  that  reported  for  the  aFGF  receptor  on 
BALB/c/3T3  cells  (6).  Studies  with  12SI-labeled aFGF  re- 
vealed that binding of the full-length protein to BALB/c/3T3 
cells is completely blocked with excess amounts of aFGF', 
supporting the notion that both forms of the protein bind 
to  a common receptor on these cells  (Fig.  6 B). 
As the truncated aFGF' does not induce mitogenesis of 
fibroblasts, we next investigated the capacity of aFGF' to evoke 
signals  that couple aFGF receptor occupancy to cellular re- 
sponses. Others have shown that aFGF increases c-j~s expres- 
sion in 3T3 cells, as assessed by Northern blot analyses (8). 
Only full-length aFGF was found to induce c-J~s expression, 
whereas an equimolar amount of aFGF' lacked this activity 
at various time points after stimulation (Fig.  7). Analysis of Figure 7.  Differential  induction  of c-fis  mRNA in fibroblasts  by aFGF 
and aFGF'. Northern  blot analysis  of total  RNA isolated  from  BALB/c/3T3 
cells stimulated with either 50 ng/ml aFGF (lane B), 18.6 ng/ml aFGF' 
(lane C), or medium alone  (lane  A). Only the result  of  30 rain after  stimu- 
lation is shown. 
the pattern of tyrosine-phosphorylated  proteins (7) in extracts 
of BALB/c/3T3 cells after stimulation with aFGF and aFGF' 
(data not shown) demonstrated that aFGF' failed to elicit the 
modification of several proteins characteristically of aFGF. The 
results of both types of studies indicate that aFGF' does not 
induce biochemical or cellular events typically evoked by aFGE 
aFGF' apparently is missing structures of the fuU-length aFGF 
that are essential for receptor activation and subsequent produc- 
tive transduction of signals  to cells  (8). 
Overexpression ofaFGF'.  Transfectants of aFGF and bFGF 
in 3T3 cells have been shown to induce a transformed pheno- 
type in these cells that is characterized by excessive growth, 
loci formation, and the loss  of contact inhibition (16,  17). 
To study the function of the alternate aFGF' on growth and 
transformation in fibroblasts,  stable transfectants were gener- 
ated of aFGF' and aFGF as well as cotransfectants of aFGF 
and aFGF'.  BALB/c/3T3 fibroblasts were transfected with 
either a recombinant plasmid expressing aFGF or aFGF', or 
with both plasmids.  Fig.  8  shows the result of an RNase 
protection assay of several transfectants that were obtained. 
Whereas no bands are visible for 3T3 cells (small  amounts 
of endogenous aFGF mRNA in 3T3 cells were detected by 
the RT-PCR methodology; data not shown) or cells trans- 
fected with a plasmid with no insert (R.C1),  all  the other 
transfectant cells result in either a protected RNA species of 
504 bp for aFGF (L4, L5), two protected RNA fragments 
of 230 and 171 bp for aFGF' ($5, $7, $8), or all three RNA 
Figure 8.  RNase protection assay of transfectants. The same aFGF 
riboprobe  that was used in Fig. 3, which is complementary  to the coding 
region of the aFGF gene, was incubated with transfectant RNA and 
processed  as described  in Materials and Methods. (3T3) BALB/c/3T3 cells; 
(RCI) transfectant  with plasmid with no insert; (L4, LS) aFGF transfec- 
rants; ($5, $7, $8) aFGF' transfectants; (SL3, SL22, SL31) aFGF'/aFGF 
cotransfectants. Protected  ILNA species are 504 bp for aFGF and 230 and 
171 bp for aFGF', respectively.  The protected  46-bp 3,-actin RNA frag- 
ment is shown at the bottom of the gel. RNA molecular  mass standards 
are shown in the right lane. 
Table  1.  Proliferation  Assay of Transfected Cell Lines 
Cell number (n  =  2) 
Cell line  Exp.  1  Exp.  2 
3T3  121,200  137,400 
RC1  135,900  134,700 
$5 (aFGF')  71,100  88,800 
$7 (aFGF')  66,000  59,400 
$8 (aFGF')  56,400  54,300 
L4 (aFGF)  260,700  289,500 
L5 (aFGF)  382,800  380,100 
SL3 (aFGF'/aFGF)  110,400  105,300 
SL22 (aFGF'/aFGF)  96,000  80,100 
SL31 (aFGF'/aFGF)  68,700  77,100 
30,000 cells were grown for  5  d,  trypsinized, and  counted. 3T3 
(BALB/c/3T3 cells); RC1 (cells transfected  with plasmid with no in- 
sert); $5, $7, $8 (aFGF' transfectants);  L4, L5 (aFGF  transfectants);  SL3, 
SL22, 8L31 (aFGF'/aFGF cotransfectants). 
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cells, a higher level of aFGF' RNA as compared with aFGF 
RNA is found in SL3 (aFGF'/aFGF, 2:1) and SL31 cotrans- 
fectants (aFGF'/aFGF, 3:1), whereas the reverse is true for 
the SL22 transfectant cell line (aFGF'/aFGF, 1:2). A 46-bp 
protected 3'-actin RNA served as an internal control and re- 
vealed that equal amounts of total RNA had been used in 
the assay. Results  from Table 1 show that cells expressing 
aFGF (L4, LS) grow to a much higher density than untrans- 
fected cells (3T3)  or cells transfected with a plasmid with 
no insert  (P,  C1). In the transfectants overexpressing aFGF' 
($5, $7, $8) and cotransfectant cell lines (SL3, SL22, SL31), 
however, reduced growth rates were found as compared with 
untransfected cells. Furthermore, whereas aFGF transfectants 
were characterized by a disorganized, multilayered growth, 
all the other transfectants, including aFGF' transfectants and 
cotransfectants,  revealed  a normal monolayered  growth pattern. 
Discussion 
We describe here the discovery of an alternate mRNA form 
of the aFGF gene that encodes a truncated aFGF protein and 
can be found in several lines of cultured human cells. The 
mRNA of aFGF' is missing the entire nucleotide sequence 
of the second coding exon of the aFGF gene, as assessed by 
the RT-PCR technique. The failure to detect aFGF' mRNA 
previously is very likely due to the inability to resolve a spe- 
cies only 100 bp smaller on routine Northern blots designed 
for studies  of large  mRNAs.  Further,  the very complex 
mP,  NA pattern of the aFGF gene (12) is likely to prevent 
detection of another mRNA. PCR with primers flanking 
the coding region of aFGF generates large quantities of the 
respective  cDNA species  of aFGF and aFGF', which are readily 
separated on agarose gels (Fig. 1). Likewise, there are two 
reasons why the aFGF' protein escaped attention previously. 
Most of the available antibodies  against aFGF are directed 
against epitopes that are encoded by exons 2 and 3, and hence 
will not recognize  the alternate  aFGF' form, which is en- 
coded almost exclusively by exon 1. Furthermore, the detec- 
tion of proteins as small as aFGF' by SDS-PAGE and Western 
blot analysis required higher percentage acrylamide gels to 
prevent loss of such small proteins that otherwise run off  and 
elute out of the gel or wash off the membrane during pro- 
cessing of Western blots (18). We have found that prolonged 
incubation and washing steps indeed reduced the signal of 
the blotted aFGF' protein considerably  and also made it difficult 
to assess the exact ratio of aFGF and aFGF' in the cells. Con- 
sistent with earlier observations of the nuclear localization 
of aFGF (19), we also found that aFGF' can be detected in 
the nucleus  of cells, and  enrichment of nuclear  proteins 
provided the only way of detection of aFGF' protein.  Func- 
tional studies that were carried out with aFGF' demonstrated 
that the protein acts like an antagonist  for the full-length 
form, a potent mitogen for mesoderm- and neuroectoderm- 
derived cells. 
The binding of aFGF' to the aFGF receptor is consistent 
with studies of bFGF, which assigned the binding domain 
to amino acid sequences encoded by exon 1 (8). Studies by 
others had revealed that the heparin-binding site of aFGF is 
caused by a sequence of basic amino acids encoded by exon 
3 of the aFGF gene (8). The structures  encoded by exon 3 
are missing in the alternate form due to the early termina- 
tion of translation. The structures of aFGF encoded by exons 
2 and 3, which are deleted from aFGF', appear to be impor- 
tant for receptor activation, since aFGF' lacks mitogenic ac- 
tivity, and antagonizes the effects of aFGF. This antagonistic 
effect was found in mitogenesis assays  with murine fibroblasts 
and human endothelial cells. Similar effects were also found 
when aFGF' was overexpressed either by itself or together 
with aFGF in  murine fibroblasts  that express only small 
amounts of endogenous aFGF and aFGF', as detected by the 
KT-PCK methodology, aFGF' transfectant cell lines showed 
reduced growth rates as compared with aFGF transfectant 
or untransfected  cells. These effects are consistent  with an 
internal autocrine mechanism that has been proposed  as a 
way for cellular transformation (20). In contrast to the ex- 
ternal autocrine mechanism, ligands, in this case aFGF and 
aFGF', and their specific receptor interact  with each other 
inside the cell, for instance, along the secretory pathway, to 
generate a stimulatory signal (20). Based on this model, we 
assume that in the cotransfectant cell lines, aFGF' competi- 
tively inhibits  the transforming activities of aFGF. 
The discovery  of a natural antagonist for the potent mitogen 
aFGF, which appears to be generated by alternate  splicing 
of pre-mRNA, provides a novel mechanism for control of 
cell growth stimulated by polypeptide growth factors. Since 
the presumed nuclear translocation  sequence of aFGF is en- 
coded by exon 1 (19), and hence preserved in the aFGF' struc- 
ture, it is conceivable that the alternate form also gets trans- 
located into the nucleus of the cells, which is consistent with 
our Western blot results. There is no current evidence for 
regulation of cell growth by aFGF' in vivo. However, it is 
attractive to assume that initiation of a proliferative response 
by aFGF also results in upregulation of the expression  of aFGF', 
subsequent blocking of binding sites on the FGF receptor 
by the antagonist,  and downregulation of the proliferative 
response of the target cells. To study the modulation of the 
mitogenic effect of aFGF by aFGF' in cellular growth, we 
are currently investigating if there are differences in the ratio 
of the two proteins  at different stages of the cell cycle. As 
both forms of aFGF are made by the same cell, it is conceiv- 
able that this mechanism is important in normal regulation 
of cell growth and differentiation,  and may be impaired in 
cancerous growth or abnormal tissue fibrosis. 
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